KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 0.13.

  • Novavax's Equity Ratio rose 5680.53% to 0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.13, marking a year-over-year increase of 5680.53%. This contributed to the annual value of 0.4 for FY2024, which is 23.62% down from last year.
  • Per Novavax's latest filing, its Equity Ratio stood at 0.13 for Q3 2025, which was up 5680.53% from 0.03 recorded in Q2 2025.
  • Novavax's 5-year Equity Ratio high stood at 0.4 for Q1 2021, and its period low was 0.64 during Q1 2024.
  • For the 5-year period, Novavax's Equity Ratio averaged around 0.19, with its median value being 0.24 (2024).
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 64522.76% in 2021, then tumbled by 261933.14% in 2023.
  • Novavax's Equity Ratio (Quarter) stood at 0.14 in 2021, then crashed by 105.69% to 0.28 in 2022, then plummeted by 42.08% to 0.4 in 2023, then fell by 0.24% to 0.4 in 2024, then surged by 66.79% to 0.13 in 2025.
  • Its Equity Ratio stands at 0.13 for Q3 2025, versus 0.03 for Q2 2025 and 0.06 for Q1 2025.